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Abstract
Background: Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat 
expansion within the huntingtin gene. Mutant huntingtin protein misfolds and accumulates within neurons where it 
mediates its toxic effects. Promoting mutant huntingtin clearance by activating macroautophagy is one approach for 
treating Huntington's disease (HD). In this study, we evaluated the mTOR kinase inhibitor and macroautophagy 
promoting drug everolimus in the R6/2 mouse model of HD.
Results: Everolimus decreased phosphorylation of the mTOR target protein S6 kinase indicating brain penetration. 
However, everolimus did not activate brain macroautophagy as measured by LC3B Western blot analysis. Everolimus 
protected against early declines in motor performance; however, we found no evidence for neuroprotection as 
determined by brain pathology. In muscle but not brain, everolimus significantly decreased soluble mutant huntingtin 
levels.
Conclusions: Our data suggests that beneficial behavioral effects of everolimus in R6/2 mice result primarily from 
effects on muscle. Even though everolimus significantly modulated its target brain S6 kinase, this did not decrease 
mutant huntingtin levels or provide neuroprotection.
Background
Huntington's disease (HD) is a progressive neurodegener-
ative disorder caused by a glutamine-encoding CAG
repeat expansion within the huntingtin gene [1]. Neuro-
degeneration is most prominent within striatum and neo-
cortex and results in abnormal movements, cognitive
decline and psychiatric symptoms. Mutant huntingtin
misfolds and accumulates as soluble and insoluble aggre-
gated species primarily in neurons.
Macroautophagy is a lysosomal-dependent process that
mediates the turnover of organelles and misfolded pro-
teins that are too large to be degraded by the ubiquitin
proteosomal system [2,3]. Steps involve biochemical
induction, the sequestering of cytoplasmic fragments into
double-membrane bound autophagic vacuoles, subse-
quent fusion with lysosomes and degradation within
autolysosomes [4]. The process involves the coordinated
expression and regulation of many core and autophagy-
related [5] as well as lysosomal proteins [6]. There is acti-
vation of macroautophagy in HD models [3,7]. Macroau-
t o p h a g y  i s  a l s o  i n v o l v e d  i n  t h e  p a t h o g e n e s i s  o f
Parkinson's, Alzheimer's and prion diseases [8-10].
Promoting clearance of mutant huntingtin (mhtt) by
induction of macroautophagy is one approach for treat-
ing human HD [7,11]. Everolimus (formerly called
RAD001) is an inhibitor of mammalian target of rapamy-
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cin (mTOR), a protein that is part of an intra-cellular sig-
naling pathway regulating cell metabolism. Everolimus,
like rapamycin, inhibits the kinase activity of the raptor-
mTOR complex (mTORC1) by binding to the protein
FKBP-12, which forms an inhibitory complex with mTOR
[12,13]. mTOR kinase is a cytosolic protein that receives
inputs from nutrient signaling pathways and is an inhibi-
tor of macroautophagy [14,15]. Everolimus inhibition of
mTOR kinase promotes macroautophagy in a number of
model systems [16,17]. mTOR-kinase-independent mac-
rophagy inducers have also been identified [9,11] and
these may offer an alternative pathway to modulate
autophagy. However, the class of mTOR-kinase-inhibiting
drugs is well characterized and in clinical use for their
anti-neoplastic and anti-solid organ graft rejection effects
[18,19]. These compounds would offer advantages of
availability and rapid progression into clinical trials if
found to have significant beneficial effects in HD models.
The goal of this study was to evaluate the effect of
everolimus in the R6/2 transgenic mouse model of HD.
These mice express the exon-1 encoded fragment of
mutant huntingtin under the control of the huntingtin
promoter which results in protein expression in brain and
skeletal muscle [20]. We found that everolimus retarded
declines in motor improvements. In brain, everolimus
inhibited phosphorylation of the mTOR kinase target
protein S6 kinase, but did not decrease mutant hunting-
tin levels, or decrease brain and neuronal atrophy. How-
ever, in skeletal muscle everolimus significantly
decreased levels of soluble mutant huntingtin protein.
While our data demonstrates a beneficial effect of
everolimus in R6/2 HD mice, we could not demonstrate
neuroprotection.
Results
Pharmacokinetic analysis of everolimus in R6/2 mice
Mice were treated from 6-8 weeks at 10 and 30 μmol/kg.
Plasma and brain everolimus was quantified 4 and 24
hours after the last dose. The analytical method used pro-
vided robust measures of everolimus in mouse plasma
and brain. Limits of quantification were 1.5 pmol/ml
plasma or 7.5 pmol/g brain, respectively. Four hours after
the last dose mean plasma everolimus concentrations
were 5560 and 10950 pmoles/ml at the 10 and 30 μmol/kg
doses, respectively (Figure 1A). Corresponding brain
concentrations were 113 and 299 pmoles/g (Figure 1B).
Twenty-four hours after dosing mean plasma everolimus
concentrations were significantly lower at 580 and 1160
pmoles/ml for the 10 and 30 μmol/kg doses, respectively
(Figure 1A). Corresponding mean brain concentrations at
24 hours were 57 and 154 pmoles/g (Figure 1B). Brain
everolimus was 2-3% of plasma concentration at 4-hours
consistent with plasma contamination. However, at 24
hours it was 12-14% indicating significant brain penetra-
tion (Figure 1C) (see discussion). Weight loss is a promi-
nent feature of human and mouse HD. Because pilot
tolerability experiments in R6/2 HD mice demonstrated
weight loss exceeding 10% with the 30 μmol/kg dose (our
working definition of maximum tolerated dose) we tested
10 and 20 μmol/kg doses in subsequent experiments. The
Figure 1 Everolimus penetrates the blood-brain barrier in R6/2 
HD transgenic mice. Plasma (A) and brain (B) everolimus concentra-
tions were measured 4 and 24 hours after the last dose following two 
weeks of treatment (black-bar = 10 μmol/kg, cross-hatched bar = 30 
μmol/kg). Brain/plasma ratios (calculated as the ratio of brain to plasma 
concentration × 100) are higher than the reported [29] level of blood 
contamination (~6%) at 24, but not at 4 hours (C). Shown are mean ± 
SE. n = 3.
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use of 20 μmol/kg as a maximum dose is further sup-
ported by the finding that it resulted in significantly
reduced weight gain from 6 weeks of age as compared to
vehicle-treated transgenic mice.
Everolimus decreases brain S6 kinase phosphorylation
Our pharmacokinetic analysis indicates brain penetration
of everolimus. To determine if the concentration in brain
i s  s u f f i c i e n t  t o  i n h i b i t  m T O R  k i n a s e  w e  u n d e r t o o k  a
Western blot analysis of S6 kinase, a direct phosphoryla-
tion target of mTOR kinase. We chose to evaluate everoli-
mus by dosing on Mondays, Wednesdays and Fridays for
two reasons. First, three doses/week were used when test-
ing the rapamycin and everolimus analog CCI-779 in
N171-82Q HD mice [7]. Second, in preliminary experi-
ments a single dose of 30 μmol/kg decreased brain S6
kinase phosphorylation for 24 hours (not shown). Mice
were dosed from 4-12 weeks and sacrificed 4 hours after
the last dose. S6 kinase phosphorylation at the S235-236
epitope was significantly decreased in cortex of R6/2
compared to wild-type mice (Figure 2A). Twenty, but not
10, μmol/kg everolimus resulted in a significant decrease
in S235-236 phosphorylation in cortex and striatum (Fig-
ure 2A-B). There was no effect of mutant huntingtin
expression on phosphorylation of the S240-244 epitope.
Twenty, but not 10, μmol/kg everolimus significantly
decreased phosphorylation at this epitope (Figure 2C-D).
Our pharmacokinetic studies indicated no brain penetra-
tion four hours after dosing (Figure 1C). However, West-
ern blot analysis revealed significant effects on S6 kinase
phosphorylation four hours after a final dose comprising
a total of 8 weeks treatment (Figure 2). Together, these
data suggest that after prolonged treatment brain effects
of the 20 μmol/kg dose last up to 48 hours.
Effect of everolimus on mouse performance and brain 
pathology
We evaluated the effect of 10 and 20 μmol/kg everolimus
on mouse Rota-Rod endurance. Mice were treated from 4
weeks of age. At 6 and 8 weeks of age, 10 μmol/kg everoli-
mus provided significant benefit against the decline in
Rota-Rod endurance (Figure 3A). Twenty μmol/kg
everolimus provided benefit at 6 weeks only (Figure 3A).
Ten μmol/kg everolimus had no effect on body weight,
while 20 μmol/kg resulted in a significantly lower, but not
progressively declining body weight from 6-weeks (Figure
3B). There was no effect of everolimus on mean survival
times (Figure 3C). We sought to determine if the benefi-
cial effect of everolimus is due to a protective effect in
brain. R6/2 mice have progressive declines in brain size
and increases in mutant huntingtin aggregate burden
[21]. Despite the beneficial behavioral effect of everoli-
mus, neither dose was protective against loss of brain
mass as measured by brain weight, striatal volume, stri-
atal neuronal cell body volume and nuclear aggregate
density (Figure 3D-G). Twenty μmol/kg everolimus
resulted in significantly lower brain weight, which is con-
sistent with the lower body weight at this dose (Figure
3D).
LC3B cleavage
Upon synthesis, LC3B is cleaved into the cytosolic pro-
tein LC3BI. Activation of macroautophagy leads to con-
version of LC3BI into LC3BII, a form that associates with
autophagosomes [22]. Both normalized LC3BII levels and
the LC3BI: LC3BII ratio (conversion) have been used as
measures of macroautophagy activation [22,23]. We
therefore measured these parameters in brain and muscle
of R6/2 HD mice. LC3B I/II ratios were significantly
decreased (increased conversion) in striatum, but not
cortex, of R6/2 HD mice as compared to control mice
(not shown). However, there was no effect of everolimus
on normalized LC3BII levels (Figure 4A) or LC3B conver-
sion (not shown) in R6/2 HD brain. In muscle, there was
significantly more variability in Western blot results as
compared to brain. However, there was a trend towards
increased normalized LC3BII levels in muscle of everoli-
mus treated R6/2 mice (global p-value = 0.12; Figure 4B).
Everolimus normalizes increased LAMP1 in muscle but not 
in brain
Lysosome-associated membrane protein 1 (LAMP1) is
primarily a lysosomal protein [24] that could be a good
marker for late steps in the autophagy cascade. We there-
fore measured LAMP1 protein levels in brain by immun-
ofluorescence and found significant increases in neuronal
cell bodies of striatum and cortex of 12-week R6/2 mice
(Figure 5A-B). Neuropil LAMP1 staining was not quanti-
fied, but also appeared increased in R6/2 mice. Western
blot analysis corroborated this finding in striatum, but
not cortex. Further , an effect of everolimus on LAMP1
expression in brain was not detected (Figure 5C-D). We
evaluated LAMP1 in quadriceps muscle and found that
LAMP1 was significantly increased in HD control as
compared to wild-type mice. Further, high-dose everoli-
mus significantly decreased LAMP1 close to wild-type
levels (Figure 5E-F).
Everolimus decreases soluble mutant huntingtin levels in 
muscle but not brain
Time-resolved Förster resonance energy transfer (time-
resolved FRET) is a recently described technique that can
quantify soluble mutant huntingtin (mhtt) levels [25]. We
used t his met hod t o quantify leve ls of soluble mh t t in
muscle and brain. In agreement with our previous results
we found that everolimus had no effect on soluble mutant
huntingtin levels in striatum or cortex (Figure 6A). This
result was corroborated by Western blot analysis that
revealed that monomeric mhtt levels were unaltered inFox et al. Molecular Neurodegeneration 2010, 5:26
http://www.molecularneurodegeneration.com/content/5/1/26
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occipital cortex of everolimus treated mice (not shown).
However , we found that 20 μmol everolimus decreased
soluble mutant huntingtin levels in quadriceps muscle
(Figure 6B). We then used the recently described Agarose
gel electrophoresis for resolving aggregates (AGERA)
biochemical assay to quantify mutant huntingtin aggre-
gates [26]. In agreement with the quantitative pathology
data (Figure 3G) there was no effect of everolimus on
b r a i n  a g g r e g a t e s  ( s e e  A d d i t i o n a l  f i l e  1 :  F i g u r e  S 1 A - B ) .
While everolimus decreased soluble mutant huntingtin
levels in muscle of R6/2 mice (Figure 6B), there was no
effect of everolimus on aggregated huntingtin as mea-
sured by AGERA (see Additional file 1: Figure S1C-D).
Figure 2 Mutant huntingtin and everolimus decrease S6 kinase phosphorylation in mouse HD brain. High (20 μmol/kg) but not low (10 μmol/
kg) dose everolimus significantly decreases phosphorylation of S6 kinase at the S235-236 epitopes in cortex (A) and striatum (B). High-dose everolimus 
also significantly decreases phosphorylation of S6-kinase at the S240-244 epitopes in cortex (C) and striatum (D). S6 kinase phosphorylation at S235-
236 is decreased in vehicle-treated HD compared to wild-type mice (A). Mice were treated from 4-12 weeks and sacrificed 4 hours after the last dose. 
X-axes show genotype-dose combinations. TG = transgenic, WT = wild-type. n = 10. p-values: * = < 0.05, ** = < 0.01
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Discussion
R6/2 HD mice have been used extensively in pre-clinical
drug trials and numerous compounds, including one that
promotes macroautophagy, have shown neuroprotective
effects [9,27]. We studied the effect of everolimus, a O-(2-
hydroxyethyl) chain substitution of rapamycin [28] in
these mice. We hypothesized that everolimus would
decrease mutant huntingtin levels in brain and have neu-
roprotective effects as measured by decreased brain atro-
phy. To verify that everolimus could interact with and
inhibit its target, brain mTOR kinase, we performed a
pharmacokinetic study and also evaluated the phospho-
rylation state of the mTOR target, S6 kinase. Our results
demonstrate that everolimus slowly penetrates brain at
doses of 10 and 30 μmol/kg (Figure 1). Brain: plasma
ratios 4 hours after a final dose were 2-3% which is con-
Figure 3 Everolimus provides early benefit against motor decline in R6/2 HD mice. A-B. Bars: solid black (a) = HD vehicle: cross-hatched; light 
gray (b) = low dose, dark gray (c) = high dose, white (d) = wild-type vehicle treated. WT to HD vehicle comparison significance bars are omitted for 
clarity. A. Low and high dose everolimus (10 and 20 μmol/kg, respectively) provide early, but not late, benefit against the decline in Rota-rod endur-
ance in R6/2 HD mice. B. High dose everolimus has a small negative effect on body weight. Everolimus treatment does not improve measures of sur-
vival (C), brain weight (D), striatal volume (E), cell body volume (F) and nuclear aggregate density (G). Mice were dosed from 4-weeks of age. Shown 
are means + SE. X-axes show genotype-dose combinations (D-F). TG = transgenic, WT = wild type. n = 15-20 for behavior and survival (A-C), n = 12 
for quantitative pathology (D-G). p-values: * = < 0.05
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sistent with plasma contamination (Figure 1C). However,
at 24 hours, brain: plasma ratios were 12-14% which is
significantly greater than mouse fore-brain vascular vol-
ume of ~6% indicating significant brain penetration [29].
Brain everolimus concentrations were in the range 50-
180 nM at 24 hours. The IC50 of everolimus in cell prolif-
eration assays is in the sub-nano molar range [30] which
is consistent with the concentrations we found in brain
being sufficient to strongly inhibit mTOR kinase. To
address this, we used S6 kinase phosphoepitope Western
blot analysis. We reduced our high dose from 30 to 20
μmol/kg at this point because of body weight loss follow-
ing prolonged treatment at the 30 μmol/kg dose. Even
though we did not repeat the pharmacokinetic analysis
using the 20 μmol/kg dose our Western blot analysis
clearly shows decreased S6 kinase phosphorylation at the
20 but not the 10 μmol/kg dose, confirming brain pene-
tration at the higher dose used (Figure 2). Decreased S6
kinase phosphorylation in R6/2 HD cortex at the S235-
236 epitope, as compared to wild-type mice, is consistent
with findings in the N171-82Q HD mouse [7].
Despite demonstrating penetration of everolimus into
brain and modulation of its target, we were unable to
demonstrate any protective effects in R6/2 HD mouse
brain as determined by a detailed quantitative neuropa-
thology study (Figure 3D-G) and using three independent
methods to quantify mutant huntingtin levels (Figures
3G, 6, see also Additional file 1: Figure S1) all at 12 weeks
of age. Our body weight data (Figure 3B) demonstrate
that the high (20 μmol/kg) dose we used in our efficacy
study was the maximum tolerated dose using our work-
ing definition of a 10% loss of body weight over the study
period. As brain weights were slightly but significantly
lower in the 20 μmol/kg versus placebo group (Figure
3D), this further suggests that doses higher than that used
would not have shown beneficial effects. The three times
a week dosing paradigm that we used has been reported
previously for the closely related rapamycin analog CCI-
779 in a study in N171-82Q HD mice [7]. The suitability
of this dosing frequency is also supported by our own
data in which mice sacrificed four hours after the last
dose of an eight week dosing study had decreased brain
S6 kinase phosphorylation (Figure 2) even though
everolimus did not enter brain 4 hours after a final dose
in the pharmokinetic study (Figure 1). This suggests that
with repeated, three times a week, dosing everolimus has
a prolonged effect on S6 kinase phosphorylation. Taken
together, our results suggest that failure to find a neuro-
protective effect of everolimus in R6/2 HD mice was not
due to insufficient inhibition of brain mTOR kinase activ-
ity.
Muscle is a target of mutant huntingtin in mouse and
human HD [31,32]. We found that everolimus demon-
strated an early protective effect on Rota-rod perfor-
Figure 4 Everolimus does not affect LC3BII levels in mouse HD brain. There is no significant effect of everolimus on normalized LC3BII levels in 
striatum and cortex (A). There is a trend towards increased normalized LC3BII levels in muscle of everolimus treated R6/2 mice (global p-value = 0.12) 
(B). Mice were treated from 4-12 weeks and sacrificed 4-hours after the last dose. X-axes show genotype-dose combinations. TG = transgenic, WT = 
wild-type. n = 10.
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Figure 5 Everolimus decreases LAMP1 expression in muscle, but not brain. A-B. Lysosome-associated membrane protein 1 (LAMP1) is increased 
in mouse HD striatal and cortical neurons (green) as measured by quantitative immunofluorescence. Ethidium dimer DNA/RNA counter stain (red). n 
= 5. C-D. There is no effect of everolimus on LAMP1 levels in striatum or cortex as measured by Western blot analysis. E-F. LAMP1 is increased in quad-
riceps femoris muscle; levels are significantly reduced by high-dose everolimus. Shown are means and standard errors. X-axes show genotype-dose 
combinations (C, D and F). TG = transgenic, WT = wild-type. n = 8-10. p-values: * = p < 0.05, ** = p < 0.01.
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mance that was stronger for the low (10 μmol/kg) dose
group (Figure 3A). As there was no effect of this low dose
on brain S6 kinase phosphorylation (Figure 2) we rea-
soned that a beneficial effect of everolimus in muscle
could explain why the 10 μmol/kg group performed bet-
ter than the 20 μmol/kg group on Rota-Rod analysis. We
did not measure S6 kinase phosphorylation in muscle.
H o w e v e r ,  b o t h  m T O R  a n d  S 6  k i n a s e  a r e  e x p r e s s e d  i n
muscle [33]. Given the sub-nanomolar IC50 of everolimus
for mTOR kinase and expected high penetration of
everolimus into muscle, we would expect strong suppres-
sion of S6 kinase phosphorylation. Instead, we measured
mutant huntingtin levels in everolimus treated R6/2 mice
at 12 weeks by FRET. We found significantly decreased
soluble mutant huntingtin at the high dose and a trend
towards decreased levels at the low dose (Figure 6). There
was no effect on aggregated huntingtin levels (see Addi-
tional file 1: Figure S1 C-D). Better Rota-rod performance
in the low dose group (Figure 3A) could be related to the
high dose having both beneficial and toxic effects (Figure
3B). Therefore, our data are consistent with Rota-Rod
effects of everolimus being, at least in part, due to benefi-
c ia l  e f f ects  i n  s k e l e t a l  m u s c l e .  W e  ca n n o t  ru l e  o u t  t h e
possibility of a transient suppression of mutant hunting-
tin levels in brain occurring in the 6-8 week period con-
tributing to behavioral benefits. However, as several
compounds demonstrate prolonged protective activity in
R6/2 brain [34], including one that promotes autophagy
[9,27], this would suggest that even if everolimus
decreased brain mutant huntingtin levels transiently that
mTOR kinase inhibition is not as effective as modulation
of other therapeutic targets in R6/2 mice.
LAMP1 is a type I transmembrane glycoprotein and a
marker of lysosomes and autolysosomes [24], organelles
critical for downstream steps of the autophagy cascade.
While not a core macroautophagy protein, LAMP1 is a
lysosome marker and therefore should reflect activity
within the terminal clearance steps of the autophagic cas-
cade. We evaluated LAMP1 in our study to determine if
levels are increased in R6/2 HD mice and to determine
the effect of everolimus. As expected, we found that
LAMP1 protein levels were increased in muscle and brain
(Figure 5) of R6/2 as compared to wild-type mice.
Everolimus had a significant effect on LAMP1 in muscle,
but not brain. In muscle, high dose everolimus decreased
LAMP1 towards wild-type levels and there was a trend
towards a decrease with the low dose (Figure 5E-F). This
result was unexpected and the reasons are not clear. We
speculate that everolimus may promote clearance of
autolysosomes. Further studies are clearly needed to bet-
ter understand the mechanism(s) by which everolimus
decreases mutant huntingtin and LAMP1 levels in mus-
cle.
CCI-779 is a rapamycin dihydoxymethyl propionic acid
ester [28] that has been shown to demonstrate behavioral
benefits and decrease aggregate density in N171-82Q HD
mice [7]. Our results using everolimus, a related rapamy-
cin derivative in the R6/2 HD model demonstrate a differ-
ent effect. While our data confirms entry of everolimus
into brain, as measured by direct chemical analysis and
S6 kinase phosphorylation levels, we could not demon-
Figure 6 Everolimus decreases soluble mutant huntingtin levels in muscle, but not brain. Relative quantification of soluble mutant huntingtin 
by time-resolved FRET. There is no effect of everolimus on soluble mutant huntingtin levels in striatum and cortex (A). Everolimus significantly de-
creases mean soluble mutant huntingtin in quadriceps muscle (B). X-axes = dose (μmoles/kg). ** = p < 0.01, n = 12
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strate decreased neurodegeneration or brain mutant hun-
tingtin levels. The difference between our findings and
that of Ravikumar et al (2004) could be for a number of
reasons. R6/2 HD mice have a more aggressive phenotype
than the N171-82Q HD mice used in the CCI-779 study
[21,35]. Factors such as longer polyglutamine expansion
in R6/2 compared to N171-82Q mice could also be
important.
Conclusions
Our findings suggest that mTOR kinase inhibition in R6/
2 HD mice using everolimus has, at most, a minimal
effect on disease progression in brain. Everolimus effec-
tively modulated brain S6 kinase, which is upstream of
macroautophagy induction, but had no effect on mutant
huntingtin levels. Everolimus did decrease soluble
mutant huntingtin levels in muscle. While the exact
mechanisms by which this occurs were not fully estab-
lished, our data indicates that a beneficial effect of
everolimus in muscle is a likely mechanism for the pro-
tective behavioral effects observed in our HD mice. Given
the discrepancy between our findings using everolimus in
R6/2 mice and Ravikumar et al [7] using CCI-779 in
N171-82Q mice, side-by-side testing of these molecules
in both R6/2 and N171-82Q mice, and perhaps as well in
a full-length huntingtin mouse model, would provide
additional insight into the value of this class of molecule
as a treatment for HD.
Materials and methods
Mouse studies
R6/2 mice were maintained by crossing R6/2 males (avail-
able from The Jackson Laboratory, Bar Harbor, ME) with
C57BL/6 X CBA F1 females. Tail tips were obtained at 14
days. Tail DNA CAG expansion sizes of male breeder
mice were in the range 120-130, as determined by Lara-
gen Inc. Mice were weaned at 22 days, and assigned to
treatment groups 1-2 days later. Systematic assignment to
treatment groups was used to minimize the effects of
body weight variability, litter and paternal effects.
Everolimus was prepared as described [36]. Mice were
female and were dosed by gavage on Mondays, Wednes-
days and Fridays (see discussion). Body weights were
measured weekly and used to adjust doses.
Pharmacokinetic analysis
One-hundred μl plasma was extracted three times in 500
μl ethyl acetate. Extracts were dried under a stream of
nitrogen before re-dissolving in 100 μl acetonitrile. Brains
were weighed then homogenized in water (1:5 w/v) using
an Ultra-Turrax® Mod T8 for 30 seconds. Two 100 μl ali-
quots of each homogenate were extracted thrice with 500
μl ethyl acetate, then processed as for plasma. Calibration
standards were prepared by supplementing 100 μl of
mouse plasma (from untreated animals) with everolimus
and the analysis quality monitored by routine use of an
external standard. For HPLC separation, a Nucleosil CC-
125/2 C4 reversed phase column (Macherey & Nagel,
Oensingen, Switzerland) under isocratic conditions using
60% acetonitrile and 0.05% formic acid in H2O (v/v) with
a column temperature of 40°C was used. The flow rate
was 0.35 ml/minute and sample injection volume was 10
μl. Retention times were 1.6 and 2.2 minutes for everoli-
mus and NVP-BDF461, respectively. Column efflux was
introduced directly into the ion source of a Micromass
Platform II LC detector (single quadrupole). The MS con-
ditions were as follows: ionization APCI negative polarity,
corona voltage set to 3.2 kV, fragmentor voltage (cone) 50
V, source temperature 350°C. Quantitative analysis was
performed by selected ion recording over the de-proto-
nated molecular ion [M+H-] of everolimus (m/z 956.8 ±
0.5). Peaks were integrated using MassLynx (Micromass).
Two independent extractions were analyzed per animal.
Standard curves were prepared by spiking plasma and
brain homogenates originating from untreated animals
with five concentrations of everolimus as external stan-
dard. A second set of standards in acetonitrile was
directly analyzed to estimate extraction yield. A linear
calibration was calculated for each analytical batch from
the ratio between calibrant and internal standard and the
calibrant in spiked plasma or brain samples. Regression
was performed using Origin® software. Unknown concen-
trations were calculated from the calibration parameters
obtained with extracted samples containing internal stan-
dard.
Western blot analysis
Antibodies used were: mutant huntingtin (MAB5492-
Chemicon), actin (AC40-Sigma), LC3B (Novus Biologi-
cals) and LAMP1 (BioLegend). Total S6 (54D2) and phos-
phor-S6 protein (serines 235/236 and 240/244) antibodies
(Cell Signaling). Primary antibodies were used at 1:2000,
except for AC40 (1:4000). For mutant huntingtin analysis,
dissected brain regions were homogenized in 20 volumes
of 20 mM TRIS (pH 7.2), 150 mM sodium chloride, 1 mM
EDTA, 1 mM DTT and HALT protease inhibitor cocktail
(Pierce) using a Pellet pestle®  (Kontes). Samples were
cleared at 18000 g for 15 minutes at 4°C. Thirty μg pro-
tein was resolved by SDS-PAGE and transferred to PVDF.
Membranes were blocked in 5% milk powder in TRIS-
buffered saline containing 1% Tween-20 (TBST) and then
probed with primary antibody overnight in blocking buf-
fer at 4°C. After washing and incubation in HRP-conju-
gated secondary antibody membranes were developed
using Western Lightening™ chemiluminescent reagent
plus (Perkin-Elmer). For analyses of all other proteins, the
procedure was identical to that described above except
for the homogenization buffer; this comprised 25 mMFox et al. Molecular Neurodegeneration 2010, 5:26
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HEPES (pH 7.4), 75 mM sodium chloride, 12.5 mM β-
glycerophosphate, 12.5 mM sodium fluoride, 2.5 mM
EGTA, 0.5 mM EDTA, 7.5 mM sodium pyrophosphate, 2
mM sodium vanadate, 0.1% Nonidet-P40 and HALT pro-
tease inhibitor. For muscle analysis, the same procedures
were used except that tissues were homogenized using a
Tissuemiser® (Fisher). For brain, actin was used to nor-
malize W estern blots. For muscle, we used parallel run
coomassie gels because we do not have a validated house-
keeping gene for R6/2 muscle and because actin mRNA is
down regulated in this tissue [32].
Rota-Rod Analysis
Rota-Rod endurance was assessed using an accelerating
Rota-rod (Stoelting). The rod speed accelerated from 4.5-
45 rpm at a constant rate. Measurements were first taken
prior to dosing at 3.5 weeks, then at every 2 weeks of age.
For each time point, mice were evaluated on four consec-
utive days. Day 1 was a training day. On days 2-4 acceler-
ating Rota-rod endurance was evaluated once/day up to a
maximum of 15 minutes and endurance times recorded.
The average of three trials was used for statistical analy-
sis.
Histology
At 12 weeks of age, mice were deeply anesthetized with a
tribromoethanol-based anesthetic. They were then per-
fused with freshly prepared room temperature 2% para-
formaldehyde in 0.1 M phosphate buffer (pH 7.4) for 15
minutes at a flow rate of 12 mls/minute. Perfused mice
were stored at 4°C for 2 hours prior to brain removal.
Brains were post-fixed in the same fixative overnight at
4°C prior to cryoprotection for 3 days in 10% glycerol, 2%
DMSO and 0.1 M phosphate buffer. The entire striatum
was sectioned coronally at 50 μm and every eighth sec-
tion was mounted and stained for Nissl substance using
the thionin method.
Immunostaining
Fifty-μm sections at the level of the anterior commissure
were used for immunohistochemical (IHC) staining for
mutant huntingtin aggregates and LAMP1 immunofluo-
rescence (IF). For IHC, we used a 1:2000 dilution of
EM48 antibody incubated with floating sections in PBS
containing 0.5% Tween-20 for 48 hours to aid penetrance.
After washing, sections were incubated in a biotinylated
anti-rabbit antibody overnight. Reactivity was developed
using the Vectastain ABC kit (Vector Laboratories). Sec-
tions were mounted in aqueous medium (Fluoromount
G, Southern Biotech) to prevent z-axis shrinkage. For IF,
sections were incubated in 1:100 anti-LAMP1 (BioLeg-
end) in PBS containing 0.1% Tween-20 and 10% normal
goat serum for 48 hours. Sections were washed three
times in PBS, then incubated in AlexaFluor-488 labeled
anti-rat antibody (Invitrogen) for 4-hours at 25°C. After
washing in PBS, sections were stained with the nucleic
acid stain ethidium dimer at 5 μM for 2 hours in the dark.
Sections were washed in PBS before mounting. Three-
layered z-stack images were collected using a Leica TCS
SL confocal microscope. Neurons were identified within
the central stack using ethidium dimer signal that delin-
eates nuclei and cytosol. LAMP1 signal was quantified by
outlining neuronal cell body outlines and quantifying flu-
orescence using Metamorph software (Molecular
Devices).
Stereology-
The methodologies used were exactly the same as we
have fully described previously [37].
Biochemical quantification of mutant huntingtin levels
Soluble mutant huntingtin was quantified by time-
resolved FRET as described [25]. In brief, muscle samples
were homogenized in 20 volumes of PBS containing 0.4%
(v/v) Triton-X100 and protease inhibitor using a Pre-
cellys®24 (Bertin technologies) for 2 × 30 seconds at 5000
rpm. Homogenates were cleared at 3000 rpm for 10 min-
utes at 4°C. The supernatant was transferred into a fresh
tube and total protein was measured using the BCA-Pro-
tein detection kit (Perbio, Cramlington, UK). Brain sam-
ples were homogenized in 25 mM HEPES (pH 7.4), 75
mM sodium chloride, 12.5 mM beta-glycerophosphate,
12.5 mM sodium fluoride, 2.5 mM EGTA, 0.5 mM EDTA,
7.5 mM sodium pyrophosphate, 2 mM sodium vanadate,
1 mM dithiothreitol, 0.1% nonidet p40, and 0.1% HALT
protease inhibitor. The amount of homogenate needed to
reach levels in the linear range of time-resolved FRET
detection was determined and resulted in 2 μl of homoge-
nate for brain samples (~12 μg protein/well), and 5 μl of
homogenate for muscle samples (~17 μg protein/well).
Brain or muscle homogenates were mixed with an anti-
body solution (5 μl) composed of 2B7-Europium-
Cryptate (1 ng) and MW1-d2 (10 ng) dissolved in
NaH2PO4 (50 mM, pH 7.4), NaF (400 mM), BSA (0.1% w/
v), and Tween 20, (0.05% v/v) in a low-volume 384-well
plate and incubated at 4 degrees centigrade overnight.
The final volume was 15 μl. Time-resolved FRET with
excitation at 320 nm and emission at 620 and 665 nm was
measured using an Envision fluorimeter (Perkin-Elmer).
Time-resolved FRET signals are given as the 665/620 nm
ratio. Background levels (wild-type) were deducted and
values normalized for protein concentration. Results are
expressed as a percentage of vehicle treated animals.
Aggregated huntingtin was quantified using the recently
described agarose gel electrophoresis for resolving aggre-
gates (AGERA) method [26]. Briefly, mouse brain sam-
ples were homogenized in 10 volumes (w/v) tris-saline
(100 mM Tris, pH 7.4, 150 mM NaCl) and Complete Pro-Fox et al. Molecular Neurodegeneration 2010, 5:26
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tease Inhibitor (Roche Diagnostics) by 10 ultrasound
pulses with a Branson sonifier and stored at −80°C. For
1.7% agarose gels, 1.7 g agarose (Biorad, #161-3101) was
dissolved in 100 mL 375 mmol/L Tris-HCl, pH 8.8 and
brought to boiling in a microwave oven. After melting,
SDS was added to a final concentration of 0.1% (w/v).
Gels were poured on short Biorad DNA Sub Cell™ trays.
Samples were diluted 1: 1 into non-reducing Laemmli
sample buffer (150 mmol/L Tris-HCl pH 6.8, 33% glyc-
erol, 1.2% SDS and bromophenol blue) and incubated for
20 minutes at 95°C. Two-hundred μg of protein was
loaded per AGERA lane. After loading, gels were run in
Laemmli running buffer (192 mmol/L glycine, 25 mmol/L
Tris-base, 0.1% (w/v) SDS) at 100 V, 2 A until the bro-
mophenol blue running front reached the bottom of the
gel. Semi-dry electroblotter model B (Ancos, Højby, Den-
mark) was used to blot the gels on PDVF membranes
(Millipore) at 200 mA for 1 hour. Membranes were then
developed using MW8 mouse monoclonal antibodies (3
μg/ml), and aggregate quantification performed by densi-
tometry analysis.
Statistical analysis
All data was analyzed using SAS version 9.1 software
(Cary, NC). Rota-rod and body weight data was analyzed
using a mixed-model method that included age by treat-
ment interaction effects. Slice functions and t-tests were
used to determine significant differences. All other data
was analyzed by one-way analysis of variance (ANOVA)
using a generalized-linear model procedure followed by
pair-wise comparisons. All p-values < 0.05 were consid-
ered significant.
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